
FOXO4-DRI
Designer peptide studied for clearing out old, worn-out "senescent" cells linked to ageing.
For Research Use Only
Sold strictly for laboratory research. Not for human or veterinary use, ingestion, or clinical/diagnostic application.
Pricing coming soon
Contact us for a quote on this batch.
Bacteriostatic water included
About this peptide
FOXO4-DRI is an engineered research peptide built with reversed 'mirror-image' (D-form) amino acids—a molecular modification designed to resist rapid breakdown by the body's natural enzymes, allowing it to remain stable and active far longer. As cells age, some stop dividing but refuse to die — these "senescent" cells build up and release inflammatory signals. FOXO4-DRI is studied for selectively pushing these zombie cells to self-destruct. A landmark 2017 study published in the peer-reviewed scientific journal Cell showed that FOXO4-DRI restored physical stamina, renewed coat density (hair regrowth), and improved kidney function in aged mice.
Why researchers reach for FOXO4-DRI
Senolytic research
Studied for selectively triggering the death of senescent cells while leaving healthy cells untouched.
Tissue-ageing models
Restored fitness, fur density and kidney function in naturally aged and accelerated-ageing mice.
Stable D-peptide design
Its retro-inverso structure resists breakdown, giving a longer active window than a normal peptide.
Key features
- 98%+ purity verified by HPLC
- D-retro-inverso FOXO4 peptide
- Lyophilised powder for stability
- 10 mg research vial
- Bacteriostatic water included
- For laboratory research use only
How it works
FOXO4–p53 disruption
In senescent cells, FOXO4 holds p53 in the nucleus to keep the cell alive; FOXO4-DRI competes for that binding.
p53 release
Freed p53 moves to the mitochondria, where it switches on the cell's built-in self-destruct (apoptosis) programme.
Selective targeting
Healthy cells do not rely on this FOXO4–p53 interaction, so they are largely spared.
Research dosage guidelines
Reference ranges only — reproduced from published preclinical literature. Not a recommendation for human use.
| Range | Reported dose | Note |
|---|---|---|
| Reported research range | 250–500 mcg | Reference range for laboratory research; no human dosing study has been published. |
| Frequency | Once daily | Once-daily research schedule; no specific time of day has been established. |
| Typical reconstitution | 2 mL bacteriostatic water | Yields 5 mg/mL. |
Tracking this compound? Registered researchers can log active FOXO4-DRI protocols in their private Research Log.
Timing in research protocols
Once daily — no specific time of day has been established.
- The research schedule uses one administration per day.
- No human trial has established a preferred clock time or meal relationship.
Drawn from published research protocols and pharmacology literature. Reference information for laboratory research only — not an instruction or guidance for use.
Technical specifications
- Scientific name
- FOXO4 D-retro-inverso peptide (FOXO4-DRI)
- Sequence
- D-amino-acid retro-inverso FOXO4 (86-131) fused to HIV-TAT cell-penetrating sequence
- CAS number
- 2460055-10-9
- Molecular weight
- ~5358 Da
- Purity
- 98%+ (HPLC)
- Form
- Lyophilised white powder
- Vial size
- 10 mg
- Reconstitution
- 2 ml bacteriostatic water
- Storage (unopened)
- -20 degrees C, protected from light
- Storage (reconstituted)
- 2-8 degrees C, use within 30 days
Published research
Peer-reviewed literature on FOXO4-DRI. Links open in a new tab.
Research use notice
FOXO4-DRI is supplied strictly for laboratory research. Published data are preclinical only and no human dosing protocols exist. Not for human or veterinary use, ingestion, or clinical application.
